Keywords: positive, data, introgen, ingn, therapeutics, reported, promising

Positive data for Introgen's INGN 401

Article | 22 November 2004

Print This

Introgen Therapeutics has reported promising preclinical findings for its INGN 401, a nanoparticle formulation of the tumor suppressor gene FUS1.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in